Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States

被引:55
|
作者
Paik, James M. [1 ]
Golabi, Pegah [1 ]
Biswas, Rakesh [1 ]
Alqahtani, Saleh [2 ]
Venkatesan, Chapy [1 ]
Younossi, Zobair M. [1 ,3 ]
机构
[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
[2] Johns Hopkins Univ Hosp, Div Gastroenterol & Hepatol, Baltimore, MD 21287 USA
[3] Inova Fairfax Med Campus, Dept Med, Ctr Liver Dis, 3300 Gallows Rd, Falls Church, VA 22042 USA
关键词
BURDEN; EPIDEMIOLOGY; CONSUMPTION;
D O I
10.1002/hep4.1510
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the United States, chronic viral hepatitis B and C (CHB and CHC), nonalcoholic fatty liver disease (NAFLD), and alcohol-related liver disease (ALD) are the main causes of liver deaths attributable to hepatocellular carcinoma (HCC) and cirrhosis. Our aim was to assess the changes in the rates of mortality and years of potential life lost (YLL) for HCC and cirrhosis due to different liver diseases. We used multiple-cause mortality data (2007-2017) from the National Center for Health Statistics. Annual percentage change (APC) in age-standardized death rate per 100,000 (ASDR) and age-standardized years of life lost per 100,000 (ASYLLR) were calculated. In the United States in 2017, there were 2,797,265 deaths with 73,424 liver deaths, contributing to 1,467,742 of YLL. Of the liver deaths, HCC was noted in 12,169 (16.6%) and cirrhosis in 60,111 (82.0%). CHC was responsible for 50.4% of HCC deaths; NAFLD, 35.4%; HBV, 6.0%; ALD, 5.4%; and others, 2.8%. NAFLD was responsible for 48.9% of cirrhosis deaths; ALD, 34.7%; CHC, 12.3%; CHB, 0.9%; and others, 3.2%. Between 2007 and 2017, the increase in ASDR for HCC due to ALD and NAFLD accelerated after 2014 (APC, 11.38% and 6.55%, respectively) whereas CHC stabilized (APC, 0.63%; P = 0.272) after 2011. The increase in ASYLLR of HCC escalated after 2014 for ALD and NAFLD (APC, 12.12% and 6.15%, respectively) and leveled out for CHC after 2012 (APC, -1.05%; P = 0.056). Furthermore, the highest annual increase in ASDR and ASYLLR for cirrhosis was due to ALD (APC, 3.24% and 3.34%, respectively) followed by NAFLD (APC, 1.23% and 0.49%, respectively). Conclusion: Over the past decade, ASDR and ASYLLR due to ALD and NAFLD have been increasing in the United States. The rising burden of HCC and cirrhosis are primarily driven by NAFLD and ALD.
引用
收藏
页码:890 / 903
页数:14
相关论文
共 50 条
  • [21] Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality
    Younossi, Zobair
    Henry, Linda
    GASTROENTEROLOGY, 2016, 150 (08) : 1778 - 1785
  • [22] The interaction of nonalcoholic fatty liver disease and smoking on mortality among adults in the United States
    Wijarnpreecha, Karn
    Scribani, Melissa
    Kim, Donghee
    Kim, W. Ray
    LIVER INTERNATIONAL, 2019, 39 (07) : 1202 - 1206
  • [23] POOR LIVER DISEASE AWARENESS AMONG ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN THE UNITED STATES
    Biswas, Rakesh
    Paik, James M.
    Arshad, Tamoore
    Golabi, Pegah
    Henry, Linda
    Younossi, Zobair M.
    HEPATOLOGY, 2020, 72 : 403A - 403A
  • [24] Impact of body mass index in liver transplantation for nonalcoholic fatty liver disease and alcoholic liver disease
    O'Neill, Stephen
    Napetti, Sara
    Cornateanu, Sorina
    Sutherland, Andrew I.
    Wigmore, Stephen
    Oniscu, Gabriel C.
    Adair, Anya
    HPB, 2017, 19 (12) : 1074 - 1081
  • [25] Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort
    Khoudari, George
    Singh, Amandeep
    Noureddin, Mazen
    Fritze, Danielle
    Lopez, Rocio
    Asaad, Imad
    Lawitz, Eric
    Poordad, Fred
    Kowdley, Kris, V
    Alkhouri, Naim
    WORLD JOURNAL OF HEPATOLOGY, 2019, 11 (10) : 710 - 718
  • [26] Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations
    Kovalic, Alexander J.
    Cholankeril, George
    Satapathy, Sanjaya K.
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 4
  • [27] Distinguishing nonalcoholic fatty liver disease from alcoholic liver disease: Is ANI enough?
    Carvalho Filho, Roberto J.
    Milani, Andre N.
    Sampaio, Juliana P.
    Schiavon, Leonardo L.
    Schiavon, Janaina N.
    Ferraz, Maria Lucia G.
    Silva, Antonio Eduardo B.
    GASTROENTEROLOGY, 2007, 132 (05) : 2076 - 2077
  • [28] Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort
    George Khoudari
    Amandeep Singh
    Mazen Noureddin
    Danielle Fritze
    Rocio Lopez
    Imad Asaad
    Eric Lawitz
    Fred Poordad
    Kris V Kowdley
    Naim Alkhouri
    World Journal of Hepatology, 2019, 11 (10) : 710 - 718
  • [29] Epidemiology of alcoholic and nonalcoholic fatty liver disease in China
    Fan, Jian-Gao
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 11 - 17
  • [30] Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Tilg, Herbert
    Moschen, Alexander R.
    Szabo, Gyongyi
    HEPATOLOGY, 2016, 64 (03) : 955 - 965